Cart
sales@molnova.com
BAY-1251152
CAS No. 1610358-53-6
BAY-1251152 ( —— )
Catalog No. M23710 CAS No. 1610358-53-6
(±)-BAY-1251152 is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 80 | In Stock |
|
| 5MG | 140 | In Stock |
|
| 10MG | 215 | In Stock |
|
| 25MG | 356 | In Stock |
|
| 50MG | 530 | In Stock |
|
| 100MG | 772 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBAY-1251152
-
NoteResearch use only, not for human use.
-
Brief Description(±)-BAY-1251152 is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.
-
Description(±)-BAY-1251152 is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK9
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1610358-53-6
-
Formula Weight404.4
-
Molecular FormulaC19H18F2N4O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO:50 mg/mL (123.63 mM; Need ultrasonic);H2O:< 0.1 mg/mL (insoluble)
-
SMILESN=S(CC1=CC(NC2=NC=C(F)C(C3=CC=C(F)C=C3OC)=C2)=NC=C1)(C)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Luecking, et al. Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 984. doi:10.1158/1538-7445.AM2017-984
molnova catalog
related products
-
VMY-1-103
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
-
SU-9516
A selective CDK2 inhibitor with IC50 of 22 nM; shows less potent for CDK1/CDK4(IC50=40/200 nM), no inhibition on PKC, EGFR, p38MAPK; decreases the phosphorylation of pRb, and increases caspase-3 activation.
-
BML-259
BML-259 is an inhibitor of CDK5 and CDK2 with IC50s of 64 and 98 nM, respectively. BML-259 can be used in studies about the treatment of cancer and neurodegenerative diseases.
